Hemophilia News and Research

RSS
Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.
New TSRI study integrates neuroscience and psychological research to understand sleep, memory

New TSRI study integrates neuroscience and psychological research to understand sleep, memory

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

CSL Behring awarded NHF's 2015 Corporate Leadership Award

CSL Behring awarded NHF's 2015 Corporate Leadership Award

Overexpression of cyclin E protein could lead to breast cancer, leukemia

Overexpression of cyclin E protein could lead to breast cancer, leukemia

Removing bacterial biofilms could help prevent and treat colon cancers, study suggests

Removing bacterial biofilms could help prevent and treat colon cancers, study suggests

CMC Biologics to supply bulk drug substance for Emergent BioSolutions' IXINITY

CMC Biologics to supply bulk drug substance for Emergent BioSolutions' IXINITY

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

New TSRI study points to promising new therapeutic target for Alzheimer's disease

New TSRI study points to promising new therapeutic target for Alzheimer's disease

TSRI study provides new insight into preventing diseases that cause vision loss in adults

TSRI study provides new insight into preventing diseases that cause vision loss in adults

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Scientists identify brain molecule that triggers schizophrenia-like behaviors, brain changes

Scientists identify brain molecule that triggers schizophrenia-like behaviors, brain changes

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Novo Nordisk announces U.S. launch of Novoeight for people living with hemophilia A

Male genetic diversity declined due to wealth, power rather than `survival of fittest`

Male genetic diversity declined due to wealth, power rather than `survival of fittest`

'Turbocharged' protein holds promise in hemophilia gene therapy

'Turbocharged' protein holds promise in hemophilia gene therapy

Study: New gene therapy safe, effective for patients with hemophilia B

Study: New gene therapy safe, effective for patients with hemophilia B

TSRI chemists develop innovative method for building new drug molecules

TSRI chemists develop innovative method for building new drug molecules

TSRI researchers create picture of whole dynein-dynactin structure

TSRI researchers create picture of whole dynein-dynactin structure

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.